Nature Biotechnology, Published online: 02 October 2024; doi:10.1038/s41587-024-02435-5
The FDA’s approval of the first genetically modified T cell therapy for treating a rare sarcoma is paving the way for next-generation therapies that tackle other types of solid tumors.
Source link
Leave a Comment